Sign In
Last checked at 
11 Mar 2020 15:45
11 March 2020
ConvaTec Group Plc("ConvaTec" or "the Company")Director/PDMR Shareholding
The Company announces the following change in the interests of Directors in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
On 6 March 2020, Karim Bitar, the Company's Chief Executive Officer and Frank Schulkes, the Company's Chief Financial Officer, both Executive Directors, received an additional grant of shares in accordance with the Company's remuneration policy approved by shareholders, as a result of one third of their annual bonus being paid out as deferred shares as follows; such shares to vest on the third anniversary of grant:
Karim Bitar: 55,348
Frank Schulkes: 81,318
The average of the middle market quotations of a ConvaTec share, derived from the London Stock Exchange Daily Official List for the three consecutive days from 3 March to 5 March 2020 (inclusive) of 187.90 pence was used in determining the number of shares to be granted under the deferred bonus provisions.
No consideration was paid for the grant of this award.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||
a) | Name | Karim Bitar | ||
2 | Reason for the notification | |||
a) | Position/Status | CEO | ||
b) | Initial notification/Amendment | Initial notification | ||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
a) | Name | ConvaTec Group Plc | ||
b) | LEI | 213800LS272L4FIDOH92 | ||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 10p each in ConvaTec Group Plc GB00BD3VFW73 | ||
b) | Nature of the transaction | Grant of restricted share award under bonus deferral subject only to a time based vesting condition | ||
c) | Price(s) and volume(s) | Price(s) N/A
| Volume(s) 55,348
| |
d) | Aggregated information - Aggregated volume - Price |
N/A | ||
e) | Date of the transaction | 6 March 2020 | ||
f) | Place of the transaction | Outside a trading venue | ||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||
a) | Name | Frank Schulkes | ||
2 | Reason for the notification | |||
a) | Position/Status | CFO | ||
b) | Initial notification/Amendment | Initial notification | ||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
a) | Name | ConvaTec Group Plc | ||
b) | LEI | 213800LS272L4FIDOH92 | ||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 10p each in ConvaTec Group Plc GB00BD3VFW73 | ||
b) | Nature of the transaction | Grant of restricted share award under bonus deferral subject only to a time based vesting condition | ||
c) | Price(s) and volume(s) | Price(s) N/A
| Volume(s) 81,318
| |
d) | Aggregated information - Aggregated volume - Price |
N/A | ||
e) | Date of the transaction | 6 March 2020 | ||
f) | Place of the transaction | Outside a trading venue | ||
Enquiries
Analysts and Investors
Mark Reynolds, Director Investor Relations, ConvaTec +44 (0)7551 036 625
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane / Vicky Haynes +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
About ConvaTec
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
Follow the stocks
